Full Breakdown
Advancements in China's Nuclear Technology: Isotope Production and Fusion Energy
10/20/2025, 11:25:47 AM
Breakthrough in Isotope Production
Hefu No.1 represents China's inaugural isotope production technology brand, developed from the heavy-water reactor at the Qinshan Nuclear Power Company, a subsidiary of the China National Nuclear Corporation (CNNC). This development signifies a pivotal advancement in the application of nuclear technology within the country. In alignment with national initiatives, Qinshan Nuclear Power Company has successfully established large-scale and stable production of essential medical isotopes, including Cobalt-60, Carbon-14, Lutetium-177, and Yttrium-90. This achievement has facilitated the creation of a comprehensive industrial chain that integrates independent research and development, in-house production, and market-oriented supply, thereby laying a robust foundation for the sustainable growth of China's nuclear medicine sector.
Progress in Fusion Energy Research
China's Huanliu-3 (HL-3), the nation's largest and most advanced tokamak device, is central to the exploration and development of fusion energy. Officially completed in December 2020, HL-3 achieved its first plasma discharge, marking a significant milestone in China's scientific research and innovation landscape. By December 2023, HL-3 was opened for global collaboration and, in 2024, it reached plasma current operations exceeding 1.5 million amperes for the first time.
In March 2025, HL-3 attained a plasma state with ion temperatures reaching 117 million degrees Celsius and electron temperatures of 160 million degrees. This remarkable achievement indicates a substantial improvement in the overall fusion triple product performance, suggesting that China's nuclear fusion research has transitioned into the phase of burning plasma experiments.
Technical Innovations and Integration
Both Hefu No.1 and HL-3 showcase China's commitment to independent innovation and technological advancement. The integration of a full industrial supply system in isotope production and the operational successes of HL-3 underscore the country's strategic focus on developing a self-sufficient nuclear technology framework. The HL-3 device, recognized as the largest and highest-parameter tokamak in China, exemplifies the technical advantages that the nation has achieved in the field of controlled nuclear fusion.
Official Statements & Responses
Officials from the China National Nuclear Corporation have emphasized the importance of these advancements in bolstering China's position in the global nuclear technology landscape. The successful production of medical isotopes and the progress in fusion energy are seen as critical steps toward enhancing the country's capabilities in nuclear medicine and energy generation.
Criticism & Opposition
Despite these advancements, there are concerns regarding the safety and environmental implications of nuclear technology. Critics argue that the rapid development of nuclear facilities must be accompanied by stringent safety measures to mitigate potential risks associated with nuclear energy and isotope production.
What's Next
Looking ahead, the continued collaboration on HL-3 and the expansion of isotope production capabilities are expected to play significant roles in China's nuclear strategy. Ongoing research and development efforts aim to further enhance the efficiency and safety of nuclear technologies, positioning China as a leader in the global nuclear sector.
